中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.018 seconds)

    Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties
    12.
    发明授权
    Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties 有权
    含有聚二有机硅氧烷聚合物以调节粘合剂性能的透皮递送装置

    公开(公告)号：US06730318B2

    公开(公告)日：2004-05-04

    申请号：US09924564

    申请日：2001-08-08

    Applicant: Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

    Inventor： Danyi Quan ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

    IPC: A61F1302

    CPC classification number: A61K8/891 ,  A61F9/04 ,  A61F13/122 ,  A61F2013/00374 ,  A61F2013/00497 ,  A61F2013/00906 ,  A61K8/0208 ,  A61K8/676 ,  A61K8/678 ,  A61K9/7053 ,  A61K9/7061 ,  A61Q19/00 ,  A61Q19/08

    Abstract: The adhesive capability of matrix-type transdermal devices for the delivery of drugs, cosmetics, emollients and the like is altered by incorporating into the pressure-sensitive adhesive an effective amount of a polydiorganosiloxane polymer fluid adhesion adjusting agent. The properties of the pressure-sensitive adhesive are modified to enable a matrix-type patch to adhere temporarily to the skin for a period sufficient to accomplish its desired delivery purpose and then be removed without causing skin damage or irritation and without leaving substantial adhesive residue on the skin. Polydimethylsiloxanes (dimethicones) are preferred adhesion adjusting agents and acrylic-based polymers are preferred pressure-sensitive adhesives. Matrix-type patches containing anti-wrinkle agents formulated with dimethicones in the adhesive for application to areas on the face and particularly around the eyes are especially useful.

    Abstract translation: 用于递送药物，化妆品，润肤剂等的基质型透皮装置的粘合能力通过将有效量的聚二有机硅氧烷聚合物流体粘附调节剂并入压敏粘合剂而改变。 修改压敏粘合剂的性能以使基质型贴片能够临时粘附到皮肤上足够长的时间以实现其期望的递送目的，然后在不引起皮肤损伤或刺激的情况下被除去并且不会留下大量的粘合剂残留物 皮。 聚二甲基硅氧烷（二甲基硅氧烷）是优选的粘合调节剂，丙烯酸类聚合物是优选的压敏粘合剂。 在粘合剂中用二甲硅油配制的抗皱剂的基质型贴剂适用于脸部和特别是眼睛周围的区域是特别有用的。

    Transdermal delivery system with adhesive overlay and peel seal disc
    14.
    发明授权
    Transdermal delivery system with adhesive overlay and peel seal disc 失效
    透皮贴剂和剥离密封盘

    公开(公告)号：US5662925A

    公开(公告)日：1997-09-02

    申请号：US638440

    申请日：1996-04-26

    Applicant: Charles D. Ebert ,  Werner Heiber ,  William R. Good ,  Srinivasan Venkateshwaran

    Inventor： Charles D. Ebert ,  Werner Heiber ,  William R. Good ,  Srinivasan Venkateshwaran

    IPC: A61K9/70 ,  A61L25/00

    CPC classification number: A61K9/703 ,  A61K9/7084

    Abstract: A device for administering an active agent to the skin or mucosa of an individual comprising a laminated composite of an adhesive overlay, a backing layer underlying the central portion of the adhesive overlay, an active agent-permeable membrane, the backing layer and membrane defining a reservoir that contains a formulation of the active agent, a peel seal disc underlying the active agent-permeable membrane, a heat seal about the periphery of the peel seal disc, the active agent-permeable membrane and the backing layer and a removable release liner underlying the exposed overlay and peel seal disc. The adhesive layer is above and peripheral to the path of the active agent to the skin or mucosa and is protected from degradation by the components of the reservoir by a multiplicity of heat seals. The peel seal disc protects against release of the active agent-containing reservoir and the release liner protects the adhesive from exposure to the environment prior to use.

    Abstract translation: 一种用于向个体的皮肤或粘膜施用活性剂的装置，其包括粘合剂覆盖物，粘合剂覆盖物的中心部分下方的背衬层，活性剂渗透膜，背衬层和膜的层压复合材料 储存器，其包含活性剂的制剂，活性剂渗透膜下面的剥离密封盘，围绕剥离密封盘的周边的热密封，活性剂可渗透膜和背衬层以及可移除的释放衬垫 暴露的覆盖层和剥离密封盘。 粘合剂层位于活性剂到皮肤或粘膜的路径之上和周边，并通过多种热封保护储存器的部件免于降解。 剥离密封盘防止含活性剂的储存器的释放，并且释放衬垫在使用之前保护粘合剂免于暴露于环境中。

    Progesterone Containing Oral Dosage Forms and Related Methods
    19.
    发明申请
    Progesterone Containing Oral Dosage Forms and Related Methods 审中-公开
    孕激素含有口服剂型及相关方法

    公开(公告)号：US20110312928A1

    公开(公告)日：2011-12-22

    申请号：US13204562

    申请日：2011-08-05

    Applicant: Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    Inventor： Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/57 ,  A61P15/00 ,  A61P15/18 ,  A61P15/16 ,  A61P35/00 ,  A61P19/10

    CPC classification number: A61K31/57 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866

    Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1.

    Abstract translation: 本发明提供含有孕酮的药物口服剂型和相关方法。 口服剂型各自可以包含一定量的孕酮以及药学上可接受的载体。 口服剂型可以配制成具有以下特征中的至少一种：口服剂型产生的孕代谢物平均血浆水平低于约1000nmol / L; 口服剂型产生孕烷代谢物平均血浆水平，施用单次孕酮组合物后，孕妇代谢物水平与母体孕酮水平的比例小于10：1; 当使用USP1型溶出装置在900mL具有2.0％（w / v）月桂基硫酸钠的去离子水中以100rpm进行测量时，其体外溶出速率使得口服剂型释放至少10重量％ 在前30分钟内孕酮的百分比和/或在前4小时内释放小于45重量％ 并且口服剂型产生平均血浆孕酮AUC与施用孕酮量的比例大于1.5×10-6hr / mL：1。

    Progesterone Containing Oral Dosage Forms and Related Methods
    20.
    发明申请
    Progesterone Containing Oral Dosage Forms and Related Methods 审中-公开
    孕激素含有口服剂型及相关方法

    公开(公告)号：US20110312927A1

    公开(公告)日：2011-12-22

    申请号：US12819125

    申请日：2010-06-18

    Applicant: Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Linus Fonkwe ,  Mahesh Patel ,  Srinivasan Venkateshwaran

    Inventor： Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Linus Fonkwe ,  Mahesh Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/57 ,  A61P15/00 ,  A61P15/08

    CPC classification number: A61K31/57 ,  A61K9/2018 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/4808 ,  A61K9/4858

    Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1

    Abstract translation: 本发明提供含有孕酮的药物口服剂型和相关方法。 口服剂型各自可以包含一定量的孕酮以及药学上可接受的载体。 口服剂型可以配制成具有以下特征中的至少一种：口服剂型产生的孕代谢物平均血浆水平低于约1000nmol / L; 口服剂型产生孕烷代谢物平均血浆水平，施用单次孕酮组合物后，孕妇代谢物水平与母体孕酮水平的比例小于10：1; 当使用USP1型溶出装置在900mL具有2.0％（w / v）月桂基硫酸钠的去离子水中以100rpm进行测量时，其体外溶出速率使得口服剂型释放至少10重量％ 在前30分钟内孕酮的百分比和/或在前4小时内释放小于45重量％ 并且口服剂型产生平均血浆孕酮AUC与施用孕酮量的比例大于1.5×10-6小时/ mL：1

Patent Agency Ranking